A preliminary analysis of luspatercept use and expenditure in Italy in the first semester of 2022. Letter
Ann Ist Super Sanita
.
2023 Apr-Jun;59(2):99-100.
doi: 10.4415/ANN_23_02_01.
Authors
Giuseppe Marano
1
,
Roberto Da Cas
1
,
Andrea Pierantozzi
2
,
Ilaria Ippoliti
1
,
Agnese Cangini
2
,
Francesca Menniti-Ippolito
1
,
Francesco Trotta
2
Affiliations
1
Centro Nazionale per la Ricerca e la Valutazione dei Farmaci, Istituto Superiore di Sanità, Rome, Italy.
2
Agenzia Italiana del Farmaco (AIFA), Rome, Italy.
PMID:
37337983
DOI:
10.4415/ANN_23_02_01
No abstract available
Publication types
Letter
Comment
MeSH terms
Activin Receptors, Type II
Health Expenditures*
Humans
Immunoglobulin Fc Fragments*
Italy
Substances
luspatercept
Immunoglobulin Fc Fragments
Activin Receptors, Type II